SCHEMBL4717088

SCHEMBL4717088

c1cc(Nc2cc(-c3ccc4[nH]ccc4c3)ncn2)c2ccncc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
TRPV1 Q8NER1 2/20 0.42
FYN P06241 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
PDE4B Q07343 1/20 0.39
CYP17A1 P05093 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
FGFR2 P21802 1/20 0.38
FLT3 P36888 1/20 0.38
PIK3CA P42336 2/20 0.38
MAP3K11 Q16584 2/20 0.38
IKBKE Q14164 1/20 0.37
TBK1 Q9UHD2 1/20 0.37
CCNC P24863 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719637 0.86 TRPV1 (0.48) TRPV1PDE4BCYP17A1CYP11B1CYP11B2
SCHEMBL4718692 0.82 TRPV1 (0.49) ABL1BCRTRPV1PDE4B
SCHEMBL4716052 0.82 PDE4B (0.51) ABL1BCRTRPV1PDE4B
SCHEMBL4718504 0.81 TRPV1 (0.59) ABL1BCRTRPV1PDE4B
SCHEMBL4716401 0.81 TRPV1 (0.48) ABL1BCRTRPV1PDE4B
SCHEMBL4715734 0.81 TRPV1 (0.45) ABL1BCRTRPV1FYNPDE4B
SCHEMBL4718686 0.81 ALDH1A1 (0.48) TRPV1PDE4B
SCHEMBL4717106 0.79 TRPV1 (0.43) TRPV1PDE4B
SCHEMBL4716832 0.79 TRPV1 (0.67) ABL1BCRTRPV1
SCHEMBL4716096 0.79 TRPV1 (0.46) ABL1BCRTRPV1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 MAOA 2659/4885MAOB 2409/4885ABL1 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.